Leerink Partners Reiterates a Buy Rating on Geron Corporation (GERN) With a $3 PT

Geron Corporation (NASDAQ:GERN) is one of the best biotech penny stocks to buy right now. Faisal Khurshid, an analyst from Leerink Partners, reiterated a Buy rating on Geron Corporation (NASDAQ:GERN) on July 21, keeping the associated price target at $3.00.

Is Geron Corp. (GERN) the Best Nasdaq Stock Under $5 to Buy?

A close-up of a laboratory technician in a laboratory, measuring a newly developed biopharmaceutical drug.

The analyst told investors that Geron Corporation (NASDAQ:GERN) is anticipated to report Rytelo net revenues slightly surpassing consensus expectations in its fiscal Q2 2025 results, suggesting potential growth.

Despite the challenges in its launch, Khurshid expressed optimism regarding management’s recent strategic changes, including sales force expansion and leadership turnover, stating that they may support growth in the second half of the year.

The analyst also acknowledged that while concerns about Rytelo’s market performance and toxicity issues exist, Geron Corporation’s (NASDAQ:GERN) current valuation suggests limited downside risk, suggesting a cautiously optimistic outlook for the company.

Geron Corporation (NASDAQ:GERN) is a biotechnology company that develops Imetelstat, a telomerase inhibitor in hematologic myeloid malignancies. It focuses on oncology-focused therapeutic products.

While we acknowledge the potential of GERN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GERN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.